Associate Professor of Clinical Psychiatry, Columbia University, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 69, New York, NY 10032, USA.
Expert Rev Clin Pharmacol. 2008 Mar;1(2):195-205. doi: 10.1586/17512433.1.2.195.
Duloxetine is a new antidepressant agent approved for use in major depressive disorder, generalized anxiety disorder and diabetic peripheral neuropathic pain. It potently inhibits the reuptake of serotonin and norepinephrine in the synaptic cleft. This dual mechanism of action is thought to provide a favorable pharmacological profile with regards to efficacy, onset of action and analgesic properties. Pilot studies on the efficacy of duloxetine in the treatment of dysthymia and other psychiatric disorders have also shown promising results. Duloxetine appears well tolerated and its safety profile is similar to that of the selective serotonin-reuptake inhibitors.
度洛西汀是一种新型抗抑郁药,已获准用于治疗重度抑郁症、广泛性焦虑症和糖尿病周围神经性疼痛。它能强力抑制突触间隙中 5-羟色胺和去甲肾上腺素的再摄取。这种双重作用机制被认为在疗效、作用开始和镇痛特性方面提供了有利的药理学特征。关于度洛西汀治疗恶劣心境和其他精神障碍的疗效的初步研究也显示出有希望的结果。度洛西汀的耐受性良好,其安全性与选择性 5-羟色胺再摄取抑制剂相似。